Lupin Manufacturing Solutions (LMS), a global contract research, development, and manufacturing organisation and a wholly owned subsidiary of Lupin Limited, has announced a strategic expansion of its manufacturing facility in Dabhasa. The move is aimed at enhancing its peptide development platform and strengthening its capabilities to support complex pharmaceutical programmes.
The expansion includes the addition of a new manufacturing block along with two specialised units dedicated to peptide production. These upgrades are designed to provide advanced development infrastructure and flexible manufacturing capabilities, enabling the company to cater to the growing demand for high-value, complex therapeutics.
With the pharmaceutical industry increasingly shifting toward advanced modalities such as peptides and biologics, the need for specialised manufacturing expertise has intensified. The upgraded facility will allow LMS to scale production of peptide building blocks, including protected amino acids, while maintaining high standards of quality and regulatory compliance.
Company leadership noted that the expansion reflects a broader commitment to supporting innovation in drug development. By investing in advanced infrastructure and scientific capabilities, LMS aims to strengthen its role as a trusted partner for biopharma companies developing next-generation therapies.
The enhanced facility is expected to support a wide range of development stages, from early research to commercial-scale manufacturing. This integrated approach is intended to streamline timelines and improve efficiency for clients navigating increasingly complex development pathways.
LMS leverages Lupin’s established expertise in pharmaceutical manufacturing, regulatory processes, and global supply chain management. With a team of more than 250 scientists and access to state-of-the-art facilities, the company provides end-to-end solutions across drug substances, complex chemistry, and advanced therapeutic modalities, including antibody-drug conjugates and peptides.
Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide and maintains a strong presence in key therapeutic areas such as respiratory, cardiovascular, anti-diabetic, and infectious diseases. The company supports its global operations through a network of manufacturing sites and research centres, along with a workforce of over 24,000 professionals.
The Dabhasa expansion is expected to further strengthen LMS’s position in the global peptide ecosystem, enabling it to support innovation at scale while meeting the evolving needs of the pharmaceutical industry. The company aims to accelerate the development and delivery of transformative therapies by combining scientific expertise with advanced manufacturing capabilities.
